Celcuity Inc.
Live Market Data
About Company
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). It also engages in developing of CELsignia diagnostic platform. The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is based in Minneapolis, Minnesota.
Industry Segment
Price Chart
Technical Analysis
Technical Outlook
Valuation Check
Research Reports
PTGX: Raising target price to $105.00
NEO: What does Argus have to say about NEO?
Quarterly Results
| Particulars | Sept 25 | Jun 25 | Mar 25 | Dec 24 | Sept 24 |
|---|---|---|---|---|---|
| Total Revenue (Cr) | 0 | 0 | 0 | 0 | 0 |
| Net Income (Cr) | -4.38 | -4.53 | -3.7 | -3.67 | -2.98 |
| EPS (₹) | -0.92 | -1.04 | -0.86 | -0.85 | -0.7 |
Annual Profit & Loss
| Particulars | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Total Revenue (Cr) | 0 | 0 | 0 | 0 |
| Operating Exp (Cr) | 11.33 | 6.62 | 3.94 | 2.84 |
| Net Income (Cr) | -11.18 | -6.38 | -4.04 | -2.96 |
| EPS (₹) | -2.83 | -2.69 | -2.64 | -2.21 |
Balance Sheet
| Particulars | Sept 25 | Jun 25 | Mar 25 | Dec 24 | Sept 24 |
|---|---|---|---|---|---|
| Total Assets (Cr) | 47.6 | 18.36 | 21.81 | 24.51 | 27.3 |
| Total Liabilities (Cr) | 35.9 | 13.92 | 13.15 | 12.95 | 12.33 |
| Total Equity (Cr) | 11.7 | 4.44 | 8.67 | 11.56 | 14.97 |
Key Ratios Fundamentals
Valuation
Profitability
Liquidity & Debt
Price Statistics
Pattern Unavailable
Detailed shareholding breakdown is not currently provided by the exchange.